Potential infectious etiologies of atherosclerosis: A multifactorial perspective

Emerging Infectious Diseases

Volumn 7, Issue 5, 2001, Pages 780-788

  O'Connor, Siobhán ^a   Taylor, Christopher ^b   Campbell, Lee Ann ^c   Epstein, Stephen ^d   Libby, Peter ^e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIUM IDENTIFICATION; CHLAMYDOPHILA PNEUMONIAE; CORONARY RISK; CYTOMEGALOVIRUS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; REVIEW;

EID: 0035199196     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0705.010503     Document Type: Review

References (97)

1. Emerging epidemic of cardiovascular disease in developing countries
2. Atherosclerosis - An inflammatory disease
3. The role of Chlamydia pneumoniae in cardiovascular disease
4. Chronic infection and coronary artery disease
5. Molecular mediators of arterial inflammation: A role for microbial products?
6. Infections and atherosclerosis: New clues from an old hypothesis?
7. Interleukin-1 gene expression in rabbit vascular tissue in vivo
8. Chlamydia pneumoniae and cardiovascular disease
9. Role of infection as a risk factor for atherosclerosis, myocardial infarction and stroke
10. Chronic infections and coronary heart disease: Is there a link?
11. Importance of smoking for Chlamydia pneumoniae seropositivity
12. Epidemiology of Chlamydia pneumoniae infection in a randomly selected population in a developed country
13. Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis
14. Commentary: Adjustment for potential confounders may have been taken too far
15. Chlamydia pneumoniae serology: Interlaboratory variation in microimmunofluorescence assay results
16. Standardizing Chlamydia pneumoniae assays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada)
17. Workshop on the potential role of infectious agents in cardiovascular disease and atherosclerosis
18. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis
19. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction
20. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women
21. Chlamydia pneumoniae infection and incident coronary heart disease: The Atherosclerosis Risk in Communities Study
22. Detection of Chlamydia pneumoniae in arterial tissues
23. Chlamydia pneumoniae in atherosclerotic tissue
24. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease
25. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis
26. Relationship of C. pneumoniae infection to severity of human coronary atherosclerosis
27. Relation between detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque
28. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors
29. Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells
30. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease
31. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection
32. Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes
33. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells
34. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae
35. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages
36. Antibiotic effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis
37. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits
38. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
39. Chlamydia pneumoniae induces inflammatory changes in hearts and aortas of C57BL/6J mice
40. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in ApoE-deficient mice
41. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae
42. Acceleration of the development of atherosclerosis following chronic infection with Chlamydia pneumoniae in cholesterol-fed C57BL/6J mice
43. Antibiotics in the prevention and treatment of coronary heart disease
44. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction
45. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study
46. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study
47. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study
48. Viruses and atherosclerosis: A critical review of the epidemiologic evidence
49. Infection and atherosclerosis: Emerging mechanistic paradigms
50. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research
51. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke
52. A prospective study of cytomegalovirus, herpes simplex virus I, and coronary heart disease
53. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis
54. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: The Cardiovascular Health Study
55. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy
56. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherosclerosis
57. Coronary artery disease after heart transplantation and its relation to cytomegalovirus
58. Cardiac allograft vasculopathy: A review
59. Cytomegalovirus infection associated accelerated heart allograft arteriosclerosis may impair the late function of the graft
60. Multiple infections in carotid atherosclerotic plaques
61. Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus with coronary artery and vein graft disease
62. Demonstration of cytomegalovirus nucleic acids in the coronary arteries of transplanted hearts
63. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts
64. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration
65. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis
66. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall
67. Neointimal smooth muscle cell phenotype is important in its susceptibility to cytomegalovirus (CMV) infection: A study in rat
68. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat
69. Cardiovascular diseases and oral infections
70. Possible explanation for the tooth loss and cardiovascular disease relationship
71. Identification of periodontal pathogens in atheromatous plaques
72. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men
73. Herpesvirus in atherosclerosis and thrombosis: Etiologic agents or ubiquitous bystanders?
74. Workshop on emerging issues in microbial infections and cardiovascular diseases, October 1998
75. Prospective study of pathogen burden and risk of myocardial infarction or death
76. Chlamydia pneumoniae-induced transactivation of the major immediate early promoter of cytomegalovirus: Potential synergy of infectious agents in the pathogenesis of atherosclerosis
77. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study
78. Atherosclerosis: Cell biology and proteins
79. Gender and relaxation to C-type natriuretic peptide in porcine coronary arteries
80. The effect of long-term supplementation with antioxidants
81. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not
82. Potential for antimicrobial resistance in Chlamydia pneumoniae
83. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland
84. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross-sectional prevalence study
85. A prospective study of the impact of community-based azithromycin therapy on trachoma carriage and resistance of S. pneumoniae
86. Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients
87. Chlamydial genomics and vaccine antigen discovery
88. Use of mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection
89. Report of a workshop: Disease accentuation after immunization with inactivated microbial vaccines
90. Chlamydia infections and heart disease links through antigenic mimicry
91. Proceedings of an international symposium on infection and atherosclerosis. Les Pensieres, Veyrier-du-Lac, France, December 6-9, 1998
92. Preface